Biasillo Gina, Cipolla Carlo M, Cardinale Daniela
Cardioncology Unit, Cardiology Department, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy.
Curr Oncol Rep. 2017 Aug;19(8):55. doi: 10.1007/s11912-017-0610-9.
Over the past 20 years, cancer treatments have become more effective, leading to significant improvements in survival rates. However, anticancer drugs can have several possible cardiovascular side effects; in particular, the development of left ventricular dysfunction with chemoradiation therapy can negatively affect patients' cardiac outcome, and can limit anticancer treatments. This is an ongoing issue that will continue to persist, due to the ongoing development of new antitumor agents with potential cardiotoxic effects, and the prolonged life expectancy of long-term cancer survivors. Thus, the need for cooperation between oncologists and cardiologists in the management of cancer patients has led to the development of a new medical discipline-cardio-oncology-where the issue of cardiotoxicity is a topic of intense interest and research. However, several issues remain-the proper definition and diagnosis of cardiotoxicity, as well as monitoring and treatment strategies. In this review, the current advances in cardio-oncology, limitations of current approaches, and future research fields will be discussed.
在过去20年里，癌症治疗变得更加有效，使生存率得到显著提高。然而，抗癌药物可能会产生多种潜在的心血管副作用；特别是，放化疗导致的左心室功能障碍会对患者的心脏预后产生负面影响，并可能限制抗癌治疗。由于具有潜在心脏毒性作用的新型抗肿瘤药物不断研发，以及长期癌症幸存者预期寿命的延长，这是一个持续存在且将继续存在的问题。因此，肿瘤学家和心脏病学家在癌症患者管理方面进行合作的需求催生了一门新的医学学科——心脏肿瘤学，其中心脏毒性问题是一个备受关注和研究的课题。然而，仍存在几个问题——心脏毒性的正确定义和诊断，以及监测和治疗策略。在这篇综述中，将讨论心脏肿瘤学的当前进展、当前方法的局限性以及未来的研究领域。
